- Home
- MNSB vs HURA Comparison
MNSB vs HURA Comparison
Compare MNSB & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MNSB | HURA |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | 171 | 22 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.9M | 160.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MNSB | HURA |
|---|---|---|
| Price | $23.45 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 28.3K | ★ 370.1K |
| Earning Date | 04-20-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.50 | N/A |
| Revenue Next Year | $3.77 | N/A |
| P/E Ratio | $12.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.86 | $0.41 |
| 52 Week High | $25.29 | $3.90 |
Technical Indicators
Market Signals| Indicator | MNSB | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | 47.39 |
| Support Level | $22.00 | $2.14 |
| Resistance Level | $25.16 | $2.60 |
| Average True Range (ATR) | 0.60 | 0.14 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 25.32 | 26.00 |
Price Performance
Historical ComparisonAbout MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.